Silence Therapeutics plc
SLNCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.53 | -0.35 | -1.19 |
| FCF Yield | -18.59% | -30.02% | -17.69% | 1.16% |
| EV / EBITDA | -4.97 | -1.56 | -3.82 | -8.16 |
| Quality | ||||
| ROIC | -34.70% | -59.53% | -39.06% | -48.51% |
| Gross Margin | 72.70% | 59.34% | 46.81% | 39.94% |
| Cash Conversion Ratio | 1.49 | 0.78 | 0.96 | -0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.21% | 26.91% | 47.27% | 270.55% |
| Free Cash Flow Growth | -72.23% | 14.16% | -938.74% | 148.47% |
| Safety | ||||
| Net Debt / EBITDA | 2.47 | 1.08 | 1.30 | 2.18 |
| Interest Coverage | 0.00 | -1,458.94 | -1,033.89 | -4,243.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 112.78 | 251.89 | 308.36 | -189.27 |